Aspiriant LLC’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.46M Buy
1,583
+681
+75% +$690K 0.04% 133
2025
Q4
$969K Buy
902
+335
+59% +$320K 0.03% 160
2025
Q3
$433K Sell
567
-64
-10% -$47.6K 0.01% 212
2025
Q2
$492K Sell
631
-25
-4% -$19.4K 0.02% 200
2025
Q1
$542K Buy
656
+17
+3% +$14.1K 0.02% 182
2024
Q4
$493K Sell
639
-139
-18% -$115K 0.02% 190
2024
Q3
$689K Sell
778
-3,135
-80% -$2.82M 0.03% 166
2024
Q2
$3.54M Buy
3,913
+3,195
+445% +$2.56M 0.14% 66
2024
Q1
$559K Buy
718
+9
+1% +$6.41K 0.02% 186
2023
Q4
$414K Buy
709
+69
+11% +$40.3K 0.02% 206
2023
Q3
$344K Sell
640
-59
-8% -$30.4K 0.02% 209
2023
Q2
$328K Buy
699
+19
+3% +$7.97K 0.02% 211
2023
Q1
$234K Sell
680
-27
-4% -$9.11K 0.01% 252
2022
Q4
$259K Buy
+707
New +$251K 0.01% 232
2021
Q3
Sell
-1,009
Closed -$232K 240
2021
Q2
$232K Buy
+1,009
New +$203K 0.01% 219
2020
Q4
Sell
-1,435
Closed -$212K 214
2020
Q3
$212K Buy
+1,435
New +$222K 0.02% 206
2018
Q2
Sell
-3,137
Closed -$243K 255
2018
Q1
$243K Buy
+3,137
New +$253K 0.02% 213

Other funds holding LLY

Aspiriant LLC's LLY Position: Q1 2026 in Review

Aspiriant LLC increased its Eli Lilly (LLY) stake by 75% in Q1 2026, buying an estimated $690K and bringing the position to 1,583 shares worth $1.46M. The position accounts for 0.04% of the portfolio, ranked #133.

Aspiriant LLC first reported a position in LLY in Q1 2018 and has held it in 17 quarters since. The position peaked at $3.54M in Q2 2024. 4,352 funds tracked by Wall St. Rank hold LLY as of Q1 2026.

  • Aspiriant LLC held 1,583 shares of Eli Lilly worth $1.46M as of Q1 2026.
  • Aspiriant LLC bought 681 Eli Lilly shares in Q1 2026, an estimated $690K.
  • Eli Lilly made up 0.04% of Aspiriant LLC's portfolio in Q1 2026, its #133 holding.
  • Aspiriant LLC first reported a position in Eli Lilly in Q1 2018 and has held it in 17 quarters since.
  • Aspiriant LLC's Eli Lilly position peaked at $3.54M in Q2 2024.
  • 4,352 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2026.

Based on Aspiriant LLC's 13F filing for Q1 2026, filed 12 May 2026.